CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

09 Nov 2021 16:15:04 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021

25 Oct 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

30 Sep 2021 12:08:12 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

17 Sep 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

10 Sep 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

16 Aug 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

09 Aug 2021 16:39:16 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

26 Jul 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

19 Jul 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

06 Jul 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

29 Jun 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®

28 Jun 2021 16:30:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan

28 Jun 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

03 Jun 2021 13:20:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

19 May 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

10 May 2021 17:29:53 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021

03 May 2021 08:05:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program

22 Mar 2021 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

15 Mar 2021 17:26:27 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021

04 Mar 2021 11:00:03 By Nasdaq GlobeNewswire